Filgotinib not checked

Alfasigma S.p.A. · GS-6034 · GLPG0634

FollowEvery change as it happens, and a Monday email
Stage
in the EU and EU
Next date
Phase 3 trial completes
Trials
12 active
18 in total · 18 in the EU
Targets
JAK1 · JAK2 · JAK3
 

What this is

How it works
Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.JAK inhibitor Named by hand
How it’s given
“IP will be provided as commercially developed film-coated tablets or age-appropriate film- coated tablets for use in paediatric subjects aged at least 8 years and needs to be taken orally q.d. at approximately the same time every morning (with or without food)”In the company’s words, NCT07554495 on ClinicalTrials.gov
Tested for
Axial Spondyloarthritis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA), Ulcerative Colitis
Main trialPhase 3
“This study is comparing 200 milligrams (mg) of filgotinib a day with a placebo to see if filgotinib helps to treat Axial Spondyloarthritis (axSpA) and is safe to use. The study will also be comparing 200 mg with 100 mg filgotinib a day to see if the lower dose also helps to treat axSpA.”In the company’s words, NCT05785611 on ClinicalTrials.gov
Other names
GS-6034 · GLPG0634 · Jyseleca

Other drugs for Axial Spondyloarthritis

All 15 drugs for Axial Spondyloarthritis

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials18

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 4 Sep 2024 A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
Phase 3Recruiting Jun 2027 Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
Phase 3Recruiting Dec 2027 OLE Study With Filgotinib in JIA
Phase 3Recruiting Jun 2028 A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
Phase 3Completed 16 May 2025 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
Phase 3Completed 8 Sep 2026 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
Phase 1Terminated 17 Jun 2026 Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
Phase 2Not authorised not given Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID)
Phase 2Authorised not given Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID)
Phase 4Authorised not given JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients
Phase 4Ended not given PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, open-label, randomized controlled trial comparing usual care with a tailor-made approach
Phase 3Authorised not given FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial
Phase 3/4Authorised not given RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASALAZINE + HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE OR LEFLUNOMIDE (The BIO-3 trial)
Phase 4Authorised not given Filgotinib bridging in newly diagnosed rheumatoid arthritis patients (FAST RA trial); A pragmatic randomized controlled non-inferiority low intervention clinical trial
Phase 4Ended not given The effect of Janus Kinase inhibitors on the heart in Rheumatoid Arthrtis
Phase 4Authorised not given REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases
Phase 4Authorised not given Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
Phase 4Authorised not given STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Filgotinib

Following is part of Solo: you see every change to Filgotinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in